Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.38 |
| ▸ | AR | P10275 | 6/20 | 0.38 |
| ▸ | BCL6 | P41182 | 2/20 | 0.37 |
| ▸ | BCOR | Q6W2J9 | 2/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.36 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.35 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23249934 | 1.00 | CRBN (0.38) | CRBNARBCL6BCORDDB1 | |
| SCHEMBL23249988 | 0.88 | CRBN (0.37) | CRBNARBCL6BCORDDB1 | |
| SCHEMBL31595469 | 0.83 | CRBN (0.50) | CRBNARDDB1EGFR | |
| SCHEMBL23267269 | 0.81 | BCL6 (0.37) | BCL6BCOR | |
| SCHEMBL31595670 | 0.79 | BCL6 (0.46) | CRBNBCL6BCORDDB1EGFR | |
| SCHEMBL31595578 | 0.78 | BCL6 (0.47) | CRBNARBCL6BCORDDB1 | |
| SCHEMBL31595273 | 0.77 | BCL6 (0.43) | CRBNBCL6BCORDDB1GSPT1 | |
| SCHEMBL31595459 | 0.77 | MAPT (0.41) | CRBNBCL6BCORDDB1IKZF2 | |
| SCHEMBL31595268 | 0.74 | CRBN (0.49) | CRBNARBCL6BCORDDB1 | |
| SCHEMBL23249944 | 0.74 | BCL6 (0.39) | BCL6BCOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20220323457-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021077010-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | ARVINAS OPERATIONS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | CRBN 5/4885AR 3563/4885BCL6 1/4885 |
| US-20220323457-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | CRBN 5/4885AR 3563/4885BCL6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.